Balchem Co. (NASDAQ:BCPC) Stock Position Reduced by Deutsche Bank AG

Deutsche Bank AG reduced its holdings in Balchem Co. (NASDAQ:BCPC - Free Report) by 11.9% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 29,216 shares of the basic materials company's stock after selling 3,933 shares during the quarter. Deutsche Bank AG owned approximately 0.09% of Balchem worth $4,762,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. Vanguard Group Inc. lifted its position in shares of Balchem by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 3,961,487 shares of the basic materials company's stock worth $645,703,000 after buying an additional 42,693 shares during the last quarter. Geode Capital Management LLC lifted its position in Balchem by 1.0% in the 4th quarter. Geode Capital Management LLC now owns 938,504 shares of the basic materials company's stock valued at $153,000,000 after purchasing an additional 9,600 shares during the last quarter. Geneva Capital Management LLC lifted its position in Balchem by 5.1% in the 4th quarter. Geneva Capital Management LLC now owns 819,746 shares of the basic materials company's stock valued at $133,615,000 after purchasing an additional 39,877 shares during the last quarter. FMR LLC lifted its position in Balchem by 16.0% in the 4th quarter. FMR LLC now owns 576,994 shares of the basic materials company's stock valued at $94,047,000 after purchasing an additional 79,499 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in Balchem by 11.0% in the 4th quarter. JPMorgan Chase & Co. now owns 509,490 shares of the basic materials company's stock valued at $83,044,000 after purchasing an additional 50,504 shares during the last quarter. 87.91% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently weighed in on BCPC. Wall Street Zen downgraded shares of Balchem from a "buy" rating to a "hold" rating in a research report on Wednesday. Sidoti upgraded shares of Balchem to a "hold" rating in a research report on Tuesday, February 25th. Finally, HC Wainwright set a $180.00 price objective on shares of Balchem and gave the company a "buy" rating in a research report on Monday, April 28th.

Balchem Price Performance

Shares of BCPC stock traded down $1.59 during midday trading on Friday, reaching $165.96. 93,766 shares of the company were exchanged, compared to its average volume of 137,453. Balchem Co. has a 12 month low of $145.70 and a 12 month high of $186.03. The company has a market cap of $5.41 billion, a P/E ratio of 42.23, a PEG ratio of 4.41 and a beta of 0.93. The company's 50 day moving average price is $161.80 and its two-hundred day moving average price is $166.15. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.16 and a current ratio of 1.99.

Balchem (NASDAQ:BCPC - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The basic materials company reported $1.22 EPS for the quarter, missing analysts' consensus estimates of $1.25 by ($0.03). Balchem had a return on equity of 11.37% and a net margin of 13.47%. The company had revenue of $250.52 million for the quarter, compared to the consensus estimate of $245.70 million. During the same quarter last year, the firm posted $1.03 earnings per share. The firm's quarterly revenue was up 4.5% compared to the same quarter last year. On average, sell-side analysts expect that Balchem Co. will post 4.64 earnings per share for the current year.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.